ASH 2018 | Daratumumab plus Rd for newly diagnosed multiple myeloma (NDMM)
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Thierry Facon, MD, of Lille University Hospital, Lille, France, presents the interim results of the Phase III MAIA trial (NCT02252172). The trial looked at the addition of daratumumab to lenalidomide/dexamethasone (D-Rd) vs. lenalidomide/dexamethasone (Rd) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM). Excitingly, the D-Rd regimen significantly reduced the risk of progression or death, with no new safety concerns. Dr Facon was speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up